Etripamil is primarily used in the medical field as a fast-acting calcium channel blocker. It is specifically designed for the rapid treatment of paroxysmal supraventricular tachycardia (PSVT), a condition characterized by sudden episodes of rapid heart rate. The drug is administered nasally, allowing for quick absorption and onset of action, making it particularly useful for patients who need immediate relief outside of a hospital setting. Its ease of use and rapid effectiveness make it a valuable option for self-administration during PSVT episodes, reducing the need for emergency medical interventions. Etripamil is being developed with the goal of providing a convenient and efficient solution for managing acute episodes of this heart rhythm disorder.